BeOne secures FDA approval for lymphoma therapy

BeOne received FDA approval for its lymphoma therapy, a notable achievement in a crowded therapeutic area.

The agency’s review concluded that the treatment meets safety and efficacy standards, placing BeOne among the few companies with an approved option for this cancer.

At the same time, other biotech firms reported activity: CREATE Medicines announced a $122 million financing round to advance its in vivo CAR‑T platform for autoimmune diseases, and Regenxbio highlighted progress in its Duchenne gene‑therapy program.

The article also notes that the U.S. administration is searching for a new FDA commissioner, suggesting possible future regulatory changes.